NurExone Biologic (TSXV:NRX) Short-Term Capital Lease Obligation : C$0.00 Mil (As of Mar. 2025)

View and export this data going back to 2022. Start your Free Trial

What is NurExone Biologic Short-Term Capital Lease Obligation?

NurExone Biologic's Short-Term Capital Lease Obligation for the quarter that ended in Mar. 2025 was C$0.00 Mil.

NurExone Biologic's quarterly Short-Term Capital Lease Obligation increased from Sep. 2024 (C$0.00 Mil) to Dec. 2024 (C$0.00 Mil) but then declined from Dec. 2024 (C$0.00 Mil) to Mar. 2025 (C$0.00 Mil).

NurExone Biologic's annual Short-Term Capital Lease Obligation declined from Dec. 2022 (C$0.03 Mil) to Dec. 2023 (C$0.02 Mil) and declined from Dec. 2023 (C$0.02 Mil) to Dec. 2024 (C$0.00 Mil).

NurExone Biologic Short-Term Capital Lease Obligation Historical Data

The historical data trend for NurExone Biologic's Short-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NurExone Biologic Short-Term Capital Lease Obligation Chart

NurExone Biologic Annual Data

Trend

Dec21

Dec22

Dec23

Dec24

Short-Term Capital Lease Obligation

0.03

0.02

NurExone Biologic Quarterly Data
	Mar21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Short-Term Capital Lease Obligation	Get a 7-Day Free Trial											-	-	-	-	-

NurExone Biologic Short-Term Capital Lease Obligation Explanation

Short-Term Capital Lease Obligation represents the total amount of Long-Term Capital Lease Obligation that must be paid within the next accounting period. Capital lease obligations are contractual obligations that arise from obtaining the use of property or equipment via a capital lease contract.

NurExone Biologic Short-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of NurExone Biologic's Short-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

NurExone Biologic Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NurExone Biologic Inc (TSXV:NRX) » Definitions » Short-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

NRXBF:USA J90:Germany

Address

1 Adelaide Street East, Suite 801, Toronto, ON, CAN, M5C 2V9

Website

https://www.nurexone.com

NurExone Biologic Inc is a company that focuses on developing biological and minimally invasive treatments for Spinal Cord Injury and Traumatic Brain Injury. Their primary product is ExoTherapy, which is an exosome therapy production platform. The company has two business lines. Firstly, it is developing ExoPTEN, a product that utilizes ExoTherapy for the treatment of acute Spinal Cord Injuries (SCI). Secondly, it aims to monetize its proprietary ExoTherapy technology and production platform by licensing it to the biopharmaceutical industry for other diseases and indications.

Executives

James Angus Wilson (bilkstys-) Richardson

10% Security Holder, Director, Senior Officer

NurExone Biologic Headlines

No Headlines